切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2019, Vol. 07 ›› Issue (04) : 254 -256. doi: 10.3877/cma.j.issn.2095-5820.2019.04.016

所属专题: 经典病例 经典病例 文献

案例讨论

原发性系统性轻链淀粉样变1例并文献复习
单士龙1,(), 楚玉兰1, 贾晓冬1, 陈建春1, 周剑峰1   
  1. 1. 300392,天津金域医学检验实验室有限公司
  • 收稿日期:2019-05-09 出版日期:2019-11-28
  • 通信作者: 单士龙

Primary systemic light chain amyloidosis: a case report and literature review

Shilong Shan1(), Yulan Chu1, Xiaodong Jia1   

  • Received:2019-05-09 Published:2019-11-28
  • Corresponding author: Shilong Shan
引用本文:

单士龙, 楚玉兰, 贾晓冬, 陈建春, 周剑峰. 原发性系统性轻链淀粉样变1例并文献复习[J]. 中华临床实验室管理电子杂志, 2019, 07(04): 254-256.

Shilong Shan, Yulan Chu, Xiaodong Jia. Primary systemic light chain amyloidosis: a case report and literature review[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2019, 07(04): 254-256.

图1 患者外周血涂片(瑞吉氏染色,×1000倍)
图2 患者骨髓活检(×10倍)
图3 心脏B超
1
中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会白血病淋巴瘤学组. 原发性轻链型淀粉样变的诊断和治疗中国专家共识(2016)[J]. 中华血液学杂志, 2016,37(9):742-746.
2
Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone(CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis[J]. Blood, 2012,119(19):4391-4394.
3
Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL amyloidosis who are ineligible for stem cell transplantation[J]. Blood, 2004,103(8):2936-2938.
4
Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis[J]. Blood, 2007,110(2):787-788.
5
Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis[J]. N Engl J Med, 2007,357(11):1083-1093.
6
Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis[J]. Blood, 2007,109(2):465-470.
7
Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis:results of a phase 2 trail[J]. Blood, 2007,109(2):492-496.
8
Sanchorawala V, Finn KT, Fennessey S, et al. Durable hematologic complete rseponses can be achieved with lenalidomide in AL amyloidosis[J]. Blood, 2010,116(11):1990-1991.
9
Dispenzieri A, Lacy M, Zeldenrust S, et al. Long term follow-up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone[J]. Blood, 2008,112(11):1737.
10
Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone for light-chain amyloidosis: long-term results from a phase 2 trial[J]. Blood, 2012,119(21):4860-4867.
11
Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis[J]. Blood, 2012,119(23):5397-5404.
12
Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain amyloidosis with the combination of bortezomib and dexamethasone[J]. Haematologica, 2007,92(10):1351-1358.
13
Zonder J, Sanchorawala V, Snyder R, et al. Rapid haematologic and organ responses in patients with AL amyloid treated with bortezomib plus melphalan and dexamethason[J]. Amyloid, 2010,17(s1):86.
No related articles found!
阅读次数
全文


摘要